Neuberger Berman Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Neuberger Berman Group’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-58,967	Closed	-$1.58M	–	1964
2022 Q1	$1.58M	Buy	58,967 +1,895	+3%	+$63.7K	﹤0.01%	1244
2021 Q4	$2.69M	Sell	57,072 -795	-1%	-$35.5K	﹤0.01%	1121
2021 Q3	$3.74M	Buy	57,867 +1,800	+3%	+$128K	﹤0.01%	1027
2021 Q2	$4.37M	Buy	56,067 +16,171	+41%	+$1.2M	﹤0.01%	995
2021 Q1	$3.77M	Buy	39,896 +19,896	+99%	+$2.37M	﹤0.01%	1013
2020 Q4	$2.44M	Buy	+20,000	New	+$2.19M	﹤0.01%	1075
2019 Q4	–	Sell	-31,098	Closed	-$1.17M	–	1615
2019 Q3	$1.17M	Sell	31,098 -22,972	-42%	-$1M	﹤0.01%	1119
2019 Q2	$2.2M	Buy	+54,070	New	+$1.93M	﹤0.01%	1008

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Neuberger Berman Group's TPTX Position: Q2 2022 in Review

Neuberger Berman Group sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 58,967 shares — an estimated $1.58M sold.

Neuberger Berman Group first reported a position in TPTX in Q2 2019 and held it in 8 quarters. The position peaked at $4.37M in Q2 2021. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

Neuberger Berman Group reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Neuberger Berman Group sold 58,967 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $1.58M.
Neuberger Berman Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
Neuberger Berman Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $4.37M in Q2 2021.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Neuberger Berman Group's 13F filing for Q2 2022, filed 15 Aug 2022.